Lupin Limited has informed the Exchange regarding a press release dated November 15, 2025, titled "Lupin Announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facilitywith No Observations".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin informed the stock exchanges that the U.S. FDA has completed its inspection of the company's Nagpur Unit-1 manufacturing facility. The inspection was closed with 'No Observations,' meaning the FDA found no objectionable conditions during its review. This is the best possible outcome from a routine FDA audit, as it indicates the facility meets all required quality and compliance standards. No Form 483 was issued, which would otherwise have flagged specific deficiencies. The Nagpur facility is a key part of Lupin's domestic and export manufacturing footprint.
This is a positive development for shareholders, as it removes any regulatory overhang on the Nagpur Unit-1 and reinforces confidence in Lupin's manufacturing quality standards. Clean FDA inspections typically support smoother approvals for products made at the facility and can be mildly positive for the stock in the short term.